Strategic Reduction of Hybrid Insulin Peptide Formation Significantly Delays Diabetes Onset in NOD Mice
- 21 October 2025
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 75 (1) , 115-123
Abstract
Type 1 diabetes (T1D) is characterized by autoimmune destruction of insulin-producing β-cells. Recent evidence has implicated hybrid insulin peptides (HIPs) as targets of autoreactive CD4 T cells in human T1D patients and as critical autoantigens recognized by diabetogenic T cells in nonobese diabetic (NOD) mice. HIPs form within pancreatic islets through cross-linking reactions between proinsulin fragments and various β-cell peptides. In the NOD mouse model, highly pathogenic CD4 T cells specifically target HIPs generated through transpeptidation mediated by cathepsin D (CatD). These disease-relevant HIPs consistently incorporate a C-peptide fragment terminating in a critical leucine residue that binds to other β-cell peptides. In vitro experiments demonstrated that substituting isoleucine for this leucine residue in human C-peptide inhibited CatD-mediated HIP formation. To investigate the in vivo significance of this finding, we engineered NOD mice carrying a leucine-to-isoleucine mutation in the insulin 2 gene (NOD INS2I/I). Mass spectrometric analysis revealed significantly reduced HIP formation in islets from NOD INS2I/I mice. Significantly decreased activation of HIP-reactive T cells to islets from these mice was also observed. Furthermore, the NOD INS2I/I mice showed significantly delayed diabetes onset, with 43% remaining disease-free at 1 year compared with only 10% of wild-type NOD controls. These findings implicate HIPs as key mediators in T1D pathogenesis and demonstrate that targeted disruption of HIP formation significantly alters disease progression. Inhibiting CatD-mediated transpeptidation represents a promising therapeutic approach for preventing or delaying T1D onset in genetically susceptible individuals. Article Highlights: Hybrid insulin peptides (HIPs) have been identified as targets of autoreactive T cells in type 1 diabetes, although their causal role in disease pathogenesis has remained unclear. We demonstrated that a single leucine-to-isoleucine substitution in insulin C-peptide significantly disrupts cathepsin D–mediated HIP formation in nonobese diabetic (NOD) mouse islets. NOD mice engineered with this precise modification (NOD INS2I/I) showed significantly reduced HIP content, decreased T-cell reactivity, and significantly delayed diabetes onset (43% disease-free at 1 year vs. 10% in controls). These findings establish a mechanistic link between HIP formation and disease progression, revealing cathepsin D–mediated transpeptidation as a potential therapeutic target for intervention in at-risk individuals.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (AI166247)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK116073)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK138763)
This publication has 31 references indexed in Scilit:
- CD4+ T cells reactive to a hybrid peptide from insulin-chromogranin A adopt a distinct effector fate and are pathogenic in autoimmune diabetesImmunity, 2024
- The insulin secretory granule is a hotspot for autoantigen formation in type 1 diabetesDiabetologia, 2024
- Mechanistic insights into CrCEP1: A dual-function cysteine protease with endo- and transpeptidase activityInternational Journal of Biological Macromolecules, 2024
- Hybrid insulin peptide isomers spontaneously form in pancreatic beta-cells from an aspartic anhydride intermediateJournal of Biological Chemistry, 2023
- Peptide−Spectrum Match Validation with Internal Standards (P−VIS): Internally-Controlled Validation of Mass Spectrometry-Based Peptide IdentificationsJournal of Proteome Research, 2020
- Identification of Hybrid Insulin Peptides (HIPs) in Mouse and Human Islets by Mass SpectrometryJournal of Proteome Research, 2018
- Transpeptidation and reverse proteolysis and their consequences for immunityThe International Journal of Biochemistry & Cell Biology, 2009
- Insulin as an autoantigen in NOD/human diabetesCurrent Opinion in Immunology, 2008
- The NOD mouse model of type 1 diabetes: As good as it gets?Nature Medicine, 1999
- The ratio of mouse insulin I:insulin II does not reflect that of the corresponding preproinsulin mRNAsMolecular and Cellular Endocrinology, 1992